1. A novel donor-derived cell-free DNA assay for the detection of acute rejection in heart transplantation
- Author
-
Kim, Paul J, Olymbios, Michael, Siu, Alfonso, Pinzon, Omar Wever, Adler, Eric, Liang, Nathan, Swenerton, Ryan, Sternberg, Jonathan, Kaur, Navchetan, Ahmed, Ebad, Chen, Yen-An, Fehringer, Gordon, Demko, Zachary P, Billings, Paul R, and Stehlik, Josef
- Subjects
Organ Transplantation ,Cardiovascular ,Transplantation ,Clinical Research ,Adult ,Biomarkers ,Cell-Free Nucleic Acids ,Graft Rejection ,Heart Transplantation ,Humans ,Tissue Donors ,acute rejection ,heart transplant ,cell free DNA ,endomyocardial biopsy ,acute cellular rejection ,antibody mediated rejection ,graft dysfunction ,Cardiorespiratory Medicine and Haematology ,Surgery - Abstract
BackgroundEndomyocardial biopsy (EMB), the reference surveillance test for acute rejection (AR) in heart transplant (HTx) recipients, is invasive, costly, and shows significant interobserver variability. Recent studies indicate that donor-derived cell-free DNA (dd-cfDNA), obtained non-invasively from blood, is associated with AR and could reduce the frequency of EMB surveillance. The aim of this study was to examine the performance characteristics of a novel test for detecting AR in adult HTx recipients.MethodsPlasma samples with contemporaneous EMBs were obtained from HTx recipients. A clinically available SNP-based massively multiplexed-PCR dd-cfDNA assay was used to measure dd-cfDNA fraction. dd-cfDNA fractions were compared with EMB-defined rejection status and test performance was assessed by constructing ROC curves and calculating accuracy measures.ResultsA total of 811 samples from 223 patients with dd-cfDNA testing and contemporaneous EMB were eligible for the study. dd-cfDNA fraction was significantly higher in AR (median 0.58%, IQR, 0.13%-1.68%) compared to non-AR (median 0.04%, IQR, 0.01%-0.11%, pc < 0.001). ROC analysis produced an area under the curve (AUC-ROC) of 0.86 (95% CI, 0.77-0.96). Defining samples with dd-cfDNA fraction ≥0.15% as AR yielded 78.5% sensitivity (95% CI, 60.7%-96.3%) and 76.9% specificity (95% CI, 71.1%-82.7%). Positive and negative predictive values were 25.1% (95% CI, 18.8%-31.5%) and 97.3% (95% CI, 95.1%-99.5%) respectively, calculated using the cohort AR prevalence of 9.0% (95% CI, 5.3%-12.8%) with adjustment for repeat samples.ConclusionsThis novel dd-cfDNA test detects AR in HTx recipients with good accuracy and holds promise as a noninvasive test for AR in HTx recipients.
- Published
- 2022